Merck loses $8M verdict in Fosamax case.
June 28, 2010
The Wall Street Journal (6/26, Bray) reported that Merck & Co. lost a product-liability suit over whether its osteoporosis drug Fosamax (alendronate) caused osteonecrosis. Bloomberg